Shares of medical technology company Abbott Laboratories (ABT.US) are up around 4% after the company reported better-than-expected second-quarter 2026 results. Revenue increased 13% year-over-year to $12.6 billion, slightly exceeding analyst estimates, while both sales and adjusted earnings came in ahead of Wall Street consensus. Although reported net income fell by around 47% to $928 million and diluted GAAP EPS declined to $0.53, investors focused primarily on stronger performance across most business segments and the company's decision to raise its full-year earnings guidance.
Abbott now expects 2026 adjusted EPS of $5.45-$5.60, up from its previous guidance range of $5.38-$5.58, representing a $0.05 increase at the midpoint. At the same time, the company reaffirmed its comparable sales growth guidance of 6.5%-7.5%, signaling confidence in stronger revenue and earnings growth during the second half of the year.
- Second-quarter revenue reached $12.6 billion, rising 13% year-over-year on a reported basis and 4.8% on a comparable basis.
- Adjusted diluted EPS came in at $1.31, while reported GAAP diluted EPS declined to $0.53.
- Net earnings fell approximately 47% year-over-year to $928 million, highlighting the difference between reported and adjusted results.
- During the first six months of 2026, revenue increased 10.5% to $23.7 billion, while net earnings declined about 35.5% to $2 billion.
- Abbott raised its full-year adjusted EPS guidance to $5.45-$5.60, compared with its previous outlook of $5.38-$5.58.
- The company maintained its comparable sales growth guidance at 6.5%-7.5% for 2026.
- Abbott returned $2.1 billion to shareholders during the quarter through dividends and share repurchases.
- The company continues expanding its product pipeline, including Libre Duo, the TECTONIC coronary IVL system, and the Amulet 360 left atrial appendage device, which could support future growth.
For investors, the key takeaway is that despite weaker reported GAAP earnings, Abbott's underlying business remains solid. The higher earnings guidance suggests management is increasingly confident that revenue growth and profitability will accelerate during the second half of the year.
Abbott share price (D1 timeframe)
Abbott shares are trading near $93 ahead of the U.S. market open, suggesting bulls may attempt to push the stock above its 50-day EMA (orange line) for the first time in several months and potentially reverse the broader downtrend. Even after today's rally, the stock remains around 30% below its all-time high.
Source: xStation5
US Open: Blood on Wall Street as Semiconductor Sector Extends Correction
UnitedHealth earnings: A show of strength and cost control
PayPal: Sale, stagnation, or revolution?
AI Stocks Slide 🚩 Dell Drops 11%
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
